Xiaoyun Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoyun Sun has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Kui Hong
Department of Medical Genetics, the Second Affiliated Hospital of Nanchang University, Nanchang 330006, China
2 shared publications - Yang Shen
Department of Medical Genetics, the Second Affiliated Hospital of Nanchang University
2 shared publications Dandan Wang
Department of Cardiovascular Medicine , The Second Affiliated Hospital of Nanchang University , Nanchang , China , jxndefy.cn
1 shared publicationJin Ouyang
Jiangxi Province Key Laboratory of Molecular Medicine , The Second Affiliated Hospital of Nanchang University , Nanchang , China , jxndefy.cn
1 shared publication- Jingxiang Chen
Department of Medical Genetics, the Second Affiliated Hospital of Nanchang University, Nanchang 330006, China
1 shared publication - Jinzhu Hu
Department of Cardiovascular Medicine, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
1 shared publication
Latest Publications
- Open Access
- 21 October 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (10) , 530
The Role of the OBSCN Gene in Cardiomyopathy: A Review of Molecular Mechanisms and Clinical Significance
Cardiomyopathies are genetically heterogeneous myocardial diseases that can lead to heart failure, arrhythmias, and sudden cardiac death. OBSCN encodes obscurin, a giant sarcomere-associated protein involved in sarcomere organization, cytoskeletal coupling, calcium handling, and cell–cell adhesion signaling. This review synthesizes current evidence on OBSCN variants in cardiomyopathy, focusing on their spectrum, phenotypic associations, and potential pathogenic mechanisms. Curated variants were systematically interpreted according to the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) guidelines. Putative truncating variants predominated among variants of uncertain significance, and hypertrophic cardiomyopathy was the most frequently reported phenotype. Co-occurring variants in established or candidate cardiomyopathy-associated genes were reported for some OBSCN variants, particularly missense variants. However, co-occurrence alone does not establish an independent pathogenic contribution, oligogenic inheritance, or a genetic modifier effect. Potential mechanisms include obscurin insufficiency, destabilization of sarcomeric scaffolding, impaired sarcoplasmic reticulum coupling, dysregulated calcium homeostasis, altered mechanotransduction, and defective intercellular adhesion. Overall, OBSCN is an emerging but incompletely characterized cardiomyopathy-associated gene, and truncating variants warrant further clinical and mechanistic investigation.
- 21 October 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (10) , 530
Open AccessThe Role of the OBSCN Gene in Cardiomyopathy: A Review of Molecular Mechanisms and Clinical Significance
Cardiomyopathies are genetically heterogeneous myocardial diseases that can lead to heart failure, arrhythmias, and sudden cardiac death. OBSCN encodes obscurin, a giant sarcomere-associated protein involved in sarcomere organization, cytoskeletal coupling, calcium handling, and cell–cell adhesion signaling. This review synthesizes current evidence on OBSCN variants in cardiomyopathy, focusing on their spectrum, phenotypic associations, and potential pathogenic mechanisms. Curated variants were systematically interpreted according to the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) guidelines. Putative truncating variants predominated among variants of uncertain significance, and hypertrophic cardiomyopathy was the most frequently reported phenotype. Co-occurring variants in established or candidate cardiomyopathy-associated genes were reported for some OBSCN variants, particularly missense variants. However, co-occurrence alone does not establish an independent pathogenic contribution, oligogenic inheritance, or a genetic modifier effect. Potential mechanisms include obscurin insufficiency, destabilization of sarcomeric scaffolding, impaired sarcoplasmic reticulum coupling, dysregulated calcium homeostasis, altered mechanotransduction, and defective intercellular adhesion. Overall, OBSCN is an emerging but incompletely characterized cardiomyopathy-associated gene, and truncating variants warrant further clinical and mechanistic investigation.
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 4229370
Functional Validation of a Novel Homozygous TTN Splice‐Site Variant Reveals Aberrant Splicing in Hypertrophic Cardiomyopathy
The TTN gene encodes a crucial structural protein within cardiac sarcomeres, and its variants may contribute to hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy; however, phenotype and genotype are different. Whole‐exome sequencing (WES) was conducted on a Chinese proband diagnosed with HCM. In silico splicing prediction tools and minigene assays were employed to investigate the impact of the identified variant on mRNA splicing. A literature review was performed to retrieve and analyze previously reported splicing variants in the TTN gene associated with HCM. A 42‐year‐old male proband presented with nonobstructive HCM and paroxysmal atrial arrhythmias. A novel homozygous TTN variant was found, predicted to cause a 14‐base pair deletion at a splice acceptor site. Two asymptomatic offspring were found to carry the heterozygous variant. Based on variant interpretation guidelines, the variant met the PM2_supporting criterion and was classified as a variant of uncertain significance (VUS). The predicted aberrant splicing effect was subsequently confirmed by the minigene splicing assay, demonstrating altered pre‐mRNA splicing leading to an in‐frame insertion/deletion (p.Arg32498_Glu32504delinsGln). Functional verification confirmed that this mutation conforms to the PM4 criterion, suggesting that it can be reclassified as a tepid VUS (scoring 3 points). The functional result might provide pathogenic evidence. We also reviewed 28 previously reported splicing variants in TTN associated with HCM. Of these, 57.1% (16/28) localized to the I‐band region, whereas 21.4% (6/28) were situated in the A‐band domain of titin. Notably, 21.4% (6/28) co‐occurred with pathogenic variants in other sarcomeric genes ( MYH7 or MYBPC3 ), correlating with more severe clinical phenotypes. Reclassification and reinterpretation of the variants revealed that none met the level of likely pathogenic or higher. The present case contributes a homozygous splice‐site variant with experimentally confirmed aberrant splicing and an in‐frame protein alteration in titin. The focus of this report is the Mendelian genetic basis of the proband′s cardiomyopathy phenotype, and our data provide additional case‐level and functional evidence for a possible role of specific TTN splicing defects in HCM.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 4229370
Open AccessFunctional Validation of a Novel Homozygous TTN Splice‐Site Variant Reveals Aberrant Splicing in Hypertrophic Cardiomyopathy
The TTN gene encodes a crucial structural protein within cardiac sarcomeres, and its variants may contribute to hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy; however, phenotype and genotype are different. Whole‐exome sequencing (WES) was conducted on a Chinese proband diagnosed with HCM. In silico splicing prediction tools and minigene assays were employed to investigate the impact of the identified variant on mRNA splicing. A literature review was performed to retrieve and analyze previously reported splicing variants in the TTN gene associated with HCM. A 42‐year‐old male proband presented with nonobstructive HCM and paroxysmal atrial arrhythmias. A novel homozygous TTN variant was found, predicted to cause a 14‐base pair deletion at a splice acceptor site. Two asymptomatic offspring were found to carry the heterozygous variant. Based on variant interpretation guidelines, the variant met the PM2_supporting criterion and was classified as a variant of uncertain significance (VUS). The predicted aberrant splicing effect was subsequently confirmed by the minigene splicing assay, demonstrating altered pre‐mRNA splicing leading to an in‐frame insertion/deletion (p.Arg32498_Glu32504delinsGln). Functional verification confirmed that this mutation conforms to the PM4 criterion, suggesting that it can be reclassified as a tepid VUS (scoring 3 points). The functional result might provide pathogenic evidence. We also reviewed 28 previously reported splicing variants in TTN associated with HCM. Of these, 57.1% (16/28) localized to the I‐band region, whereas 21.4% (6/28) were situated in the A‐band domain of titin. Notably, 21.4% (6/28) co‐occurred with pathogenic variants in other sarcomeric genes ( MYH7 or MYBPC3 ), correlating with more severe clinical phenotypes. Reclassification and reinterpretation of the variants revealed that none met the level of likely pathogenic or higher. The present case contributes a homozygous splice‐site variant with experimentally confirmed aberrant splicing and an in‐frame protein alteration in titin. The focus of this report is the Mendelian genetic basis of the proband′s cardiomyopathy phenotype, and our data provide additional case‐level and functional evidence for a possible role of specific TTN splicing defects in HCM.